Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.
about
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and predictionControversies in lupus: nervous system involvement.Neuropsychiatric adverse effects of interferon-alpha: recognition and management.Mood disorders associated with interferon treatment: theoretical and practical considerations.Pharmacotherapy of recurrent respiratory papillomatosis.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C.New antiviral and antifungal drugs.Major depression during interferon-alpha treatment: vulnerability and prevention.The chronic fatigue syndrome.Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.Central nervous system toxicity of biological response modifiers.Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?Bipolar disorder associated with interferon-alpha treatment.Chronic fatigue syndrome. 1: Etiology and pathogenesis.Psychological and immunological correlates of acute overtrainingGene expression biomarkers of response to citalopram treatment in major depressive disorderCerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C.Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study.Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population.Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser.Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.The association between depressive symptoms and insulin resistance, inflammation and adiposity in men and women.Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients.Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C.Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes.A Twin Study of the Etiology of Prolonged Fatigue and Immune ActivationImmune Function in Chronic Fatigue Syndrome and Depression
P2860
Q27477533-6C477750-C759-464C-AE99-50A2F94DE61AQ33567067-309FAF05-3AD0-495B-8DCB-F8BE7CD7C710Q34081783-3C12C47F-3B60-4F42-8434-792EBA56CA2CQ34219107-BE2762FA-C9B6-4463-BABC-1867F3F8FE84Q34768490-755A6E9C-23F4-4C3B-B74C-7962CDABD9B3Q34996746-01785A8C-EBEE-46C4-AC35-D788BAD766BFQ35087836-973D90A1-1A57-4B61-81E5-C1DAB765BF0EQ35168469-17F6B123-4B55-4B5E-AA39-63114C417054Q35237145-D2A781AB-343B-4335-8DD0-55480EDC6EEFQ35536852-93155D1C-0915-4FB8-B239-24D5FC5E8ABEQ36467826-873CF151-EC3D-4465-AEF0-5F2E17FE9E3BQ36589103-0050B46A-F257-4474-8D8A-649927CCE674Q38894095-4F17DE1D-4902-45C7-9EE3-7F71C65C19B7Q39282309-452F96B6-A846-487A-BEC2-51BA2313B3DDQ40425439-E97FCBFD-FA57-4792-B4AC-6A36AE656A81Q41305282-621FABF1-9FD5-481B-9E49-C11B514A45D0Q41910462-65F7C187-DF1A-49E5-8C7B-3D030E883EA1Q42500431-C8CFA3EB-9EF7-424D-9871-66E7334A8B0EQ43269486-6A67AAE7-43D0-471E-8CA0-CD94319B27BFQ43430812-E8237291-6A3E-4FC6-9B6E-6471164AB930Q43690599-34ABD10C-90AF-4A81-9F1E-E7699BCBDB48Q43988498-B4A3A964-E8DE-4BC8-B476-E6FE36F29D01Q45238711-1D9B6439-2537-4648-B2D2-5173A91D13E1Q45400170-A89FD77B-0A82-457A-9B39-038DC2343A5BQ47159698-BEFC7E3A-9345-4BA9-900D-B1F7C0CB2600Q48622689-2FC09E9B-9E0E-4197-AD95-5B78DC65DD23Q50575247-53006F0C-0EB1-4909-9ED4-21449A2DCF58Q51081556-7429BBDD-76AE-4C42-A177-D3980237BF88Q51922090-5B4C128B-F4D0-4E90-8ABB-879935E2CACFQ57269020-0FAC370A-F51E-4CB0-8B5B-7D9F9A9A36D2Q59200625-C91D7F73-315F-4997-8D32-249AAAE39FD5
P2860
Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@en
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@nl
type
label
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@en
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@nl
prefLabel
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@en
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@nl
P2093
P1433
P1476
Interferons as mediators of ps ...... feron in hepatitis-B carriers.
@en
P2093
E M McDonald
H C Thomas
P304
P356
10.1016/S0140-6736(87)91319-5
P407
P577
1987-11-01T00:00:00Z